press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More Heajin Kim 10/1/24 Heajin Kim 10/1/24 Read More press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More Latest Notice Mediaspace 5/2/24 Latest Notice Mediaspace 5/2/24 Read More press release Mediaspace 5/2/24 press release Mediaspace 5/2/24 Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment Read More Newer Posts Older Posts
press release Heajin Kim 2/19/25 press release Heajin Kim 2/19/25 Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment of Dry Age-Related Macular Degeneration Read More
press release Heajin Kim 10/1/24 press release Heajin Kim 10/1/24 Luxa Biotechnology LLC Appoints Keith E. Dionne, Ph.D., as Chief Executive Officer Read More
press release Mediaspace 5/2/24 press release Mediaspace 5/2/24 Luxa Biotechnology Receives $4 Million Grant for Clinical Trial of Dry AMD Treatment Read More
